Is. Oktem et al., Therapeutic effect of tirilazad mesylate (U-74006F), mannitol, and their combination on experimental ischemia, RES EXP MED, 199(4), 2000, pp. 231-242
The effect of tirilazad mesylate (U-74006F), mannitol, and their combinatio
n was investigated on focal cerebral ischemia induced by permanent middle c
erebral artery (MCA) occlusion in rabbits. Rabbits were divided into four g
roups receiving vehicle, U-74006F, mannitol, and U-74006F plus mannitol. He
matocrit (hct), glucose, mean arterial blood pressure (MABP), pH, PCO2, and
PO2 were measured both before and after occlusion. Seventy-two hours follo
wing the permanent MCA occlusion, the neurological outcome was assessed and
a quantitative neuropathologic examination was performed in all rabbits. T
he neurological outcome was better in the rabbits treated with U-74006F plu
s mannitol than in the other groups. The size of infarction of the affected
hemisphere following MCA occlusion was 49.7% in the control group, 30.6% i
n the U-74006F group, 47.6% in the mannitol group, and 24.1% in the U-74006
F plus mannitol group. There was a statistically significant reduction in i
nfarct size in the U-74006F plus mannitol group compared with the other gro
ups (P<0.05). The ratio of ischemic neurons to total neurons in the cortex
was smaller in the U-74006F plus mannitol group than in the other groups. T
he ratio of ischemic neurons to total neurons in the subcortex was signific
antly lower in the U-74006F plus mannitol group than in the other groups (P
<0.05). Our data provide evidence for the beneficial effects of both U-7400
6F and U-74006F plus mannitol in promoting neurological recovery and preser
vation of the ischemic area.